|
1
|
Welsh GI and Saleem MA: Nephrin-signature
molecule of the glomerular podocyte? J Pathol. 220:328–237.
2010.PubMed/NCBI
|
|
2
|
Niranjan T, Bielesz B, Gruenwald A, Ponda
M P, Kopp JB, Thomas DB and Susztak K: The Notch pathway in
podocytes plays a role in the development of glomerular disease.
Nat Med. 14:290–298. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ding F, Wickman L, Wang SQ, Zhang Y, Wang
F, Afshinnia F, Hodgin J, Ding J and Wiggins RC: Accelerated
podocyte detachment and progressive podocyte loss from glomeruli
with age in Alport Syndrome. Kidney Int. 92:1515–1525. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mauvais-Jarvis F, Clegg DJ and Hevener AL:
The role of estrogens in control of energy balance and glucose
homeostasis. Endocr Rev. 34:309–338. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mercantepe T, Unal D, Selli J, Mercantepe
F, Unal B and Karabiyik TN: Protective effects of estrogen and
bortezomib in kidney tissue of post-menopausal rats: An
ultrastructural study. Ren Fail. 38:1129–1135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gong W, Yu J, Wang Q, Li S, Song J, Jia Z,
Huang S and Zhang A: Estrogen-related receptor (ERR) gamma protects
against puromycin aminonucleoside-induced podocyte apoptosis by
targeting PI3K/Akt signaling. Int J Biochem Cell Biol. 78:75–86.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Doublier S, Lupia E, Catanuto P,
Periera-Simon S, Xia X, Korach K, Berho M, Elliot SJ and Karl M:
Testosterone and 17β-estradiol have opposite effects on podocyte
apoptosis that precedes glomerulosclerosis in female estrogen
receptor knockout mice. Kidney Int. 79:404–413. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thomas PE, Wharram BL, Goyal M, Wiggins
JE, Holzman LB and Wiggins RC: GLEPP1, a renal glomerular
epithelial cell (podocyte) membrane protein-tyrosine phosphatase.
Identification, molecular cloning, and characterization in rabbit.
J Biol Chem. 269:19953–19962. 1994.PubMed/NCBI
|
|
9
|
Aguiar RC, Yakushijin Y, Kharbanda S,
Tiwari S, Freeman GJ and Shipp MA: PTPROt: An alternatively spliced
and developmentally regulated B-lymphoid phosphatase that promotes
G0/G1 arrest. Blood. 94:2403–2413. 1999.PubMed/NCBI
|
|
10
|
Alonso A, Sasin J, Bottini N, Friedberg I,
Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J and Mustelin
T: Protein tyrosine phosphatases in the human genome. Cell.
117:699–711. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jacob ST and Motiwala T: Epigenetic
regulation of protein tyrosine phosphatases: Potential molecular
targets for cancer therapy. Cancer Gene Ther. 12:665–672. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ramaswamy B, Majumder S, Roy S, Ghoshal K,
Kutay H, Datta J, Younes M, Shapiro CL, Motiwala T and Jacob ST:
Estrogen-mediated suppression of the gene encoding protein tyrosine
phosphatase PTPRO in human breast cancer: Mechanism and role in
tamoxifen sensitivity. Mol Endocrinol. 23:176–187. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ozaltin F, Ibsirlioglu T, Taskiran EZ,
Baydar DE, Kaymaz F, Buyukcelik M, Kilic BD, Balat A, Iatropoulos
P, Asan E, et al: Disruption of PTPRO causes childhood-onset
nephrotic syndrome. Am J Hum Genet. 89:139–147. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Charba DS, Wiggins RC, Goyal M, Wharram
BL, Wiggins JE, McCarthy ET, Sharma R, Sharma M and Savin VJ:
Antibodies to protein tyrosine phosphatase receptor type O (PTPro)
increase glomerular albumin permeability [P(alb)]. Am J Physiol
Renal Physiol. 297:F138–F144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Staněk L: Polymerase chain reaction: Basic
principles and applications in molecular pathology. Cesk Patol.
49:119–121. 2013.(In Czech). PubMed/NCBI
|
|
16
|
Hou J, Xu J, Jiang R, Wang Y, Chen C, Deng
L, Huang X, Wang X and Sun B: Estrogen-sensitive PTPRO expression
represses hepatocellular carcinoma progression by control of STAT3.
Hepatology. 57:678–688. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rheault MN: Nephrotic and nephritic
syndrome in the newborn. Clin Perinatol. 41:605–618. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao Y, Su B G, Xiao HJ, Zhang HW, Liu XY,
Wang F and Ding J: Clinical characteristics of
glucocorticoid-induced eye adverse reactions in children with
primary nephrotic syndrome. Beijing Da Xue Xue Bao Yi Xue Ban.
49:794–797. 2017.(In Chinese). PubMed/NCBI
|
|
19
|
Bettaieb A, Koike S, Hsu MF, Ito Y, Chahed
S, Bachaalany S, Gruzdev A, Calvo-Rubio M, Lee KSS, Inceoglu B, et
al: Soluble epoxide hydrolase in podocytes is a significant
contributor to renal function under hyperglycemia. Biochim Biophys
Acta. 1861:2758–2765. 2017. View Article : Google Scholar
|
|
20
|
Ito Y, Hsu MF, Bettaieb A, Koike S, Mello
A, Calvo-Rubio M, Villalba JM and Haj FG: Protein tyrosine
phosphatase 1B deficiency in podocytes mitigates
hyperglycemia-induced renal injury. Metabolism. 76:56–69. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim NH: Podocyte hypertrophy in diabetic
nephropathy. Nephrology (Carlton). 10 Suppl:S14–S16. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Delezay O, He Z, Hodin S, Saleem MA,
Mismetti P, Perek N and Delavenne X: Glomerular filtration drug
injury: In vitro evaluation of functional and morphological
podocyte perturbations. Exp Cell Res. 361:300–307. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Abraham VC, Miller LN, Pratt SD, Putman B,
Kim L, Gopalakrishnan SM and King A: Implementation of a human
podocyte injury model of chronic kidney disease for profiling of
renoprotective compounds. Eur J Pharmacol. 815:219–232. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang S, Guo Y, Zou H, Sun N, Zhao D, Liu
W, Dong Y, Cheng G and Yuan Q: Effect of estrogen deficiency on the
fixation of titanium implants in chronic kidney disease mice.
Osteoporos Int. 26:1073–1080. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gluhovschi G, Gluhovschi A, Anastasiu D,
Petrica L, Gluhovschi C and Velciov S: Chronic kidney disease and
the involvement of estrogen hormones in its pathogenesis and
progression. Rom J Intern Med. 50:135–144. 2012.PubMed/NCBI
|
|
26
|
Ji H, Menini S, Mok K, Zheng W, Pesce C,
Kim J, Mulroney S and Sandberg K: Gonadal steroid regulation of
renal injury in renal wrap hypertension. Am J Physiol Renal
Physiol. 288:F513–F520. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ming F and Sun Q: Epigenetically silenced
PTPRO functions as a prognostic marker and tumor suppressor in
human lung squamous cell carcinoma. Mol Med Rep. 16:746–754. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wharram BL, Goyal M, Gillespie PJ, Wiggins
JE, Kershaw DB, Holzman LB, Dysko RC, Saunders TL, Samuelson LC and
Wiggins RC: Altered podocyte structure in GLEPP1 (Ptpro)-deficient
mice associated with hypertension and low glomerular filtration
rate. J Clin Invest. 106:1281–1290. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zou J, Yaoita E, Watanabe Y, Yoshida Y,
Nameta M, Li H, Qu Z and Yamamoto T: Upregulation of nestin,
vimentin, and desmin in rat podocytes in response to injury.
Virchows Arch. 448:485–492. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Barre B, Avril S and Coqueret O: Opposite
regulation of myc and p21waf1 transcription by STAT3 proteins. J
Biol Chem. 278:2990–2996. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Alvarez JV, Greulich H, Sellers WR,
Meyerson M and Frank DA: Signal transducer and activator of
transcription 3 is required for the oncogenic effects of
non-small-cell lung cancer-associated mutations of the epidermal
growth factor receptor. Cancer Res. 66:3162–3168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dudka AA, Sweet SM and Heath JK: Signal
transducers and activators of transcription-3 binding to the
fibroblast growth factor receptor is activated by receptor
amplification. Cancer Res. 70:3391–3401. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Boccaccio C, Ando M, Tamagnone L, Bardelli
A, Michieli P, Battistini C and Comoglio PM: Induction of
epithelial tubules by growth factor HGF depends on the STAT
pathway. Nature. 391:285–288. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Song L, Turkson J, Karras JG, Jove R and
Haura EB: Activation of Stat3 by receptor tyrosine kinases and
cytokines regulates survival in human non-small cell carcinoma
cells. Oncogene. 22:4150–4165. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gu F, Dube N, Kim JW, Cheng A,
Ibarra-Sanchez Mde J, Tremblay ML and Boisclair YR: Protein
tyrosine phosphatase 1B attenuates growth hormone-mediated
JAK2-STAT signaling. Mol Cell Biol. 23:3753–3762. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kleppe M, Soulier J, Asnafi V, Mentens N,
Hornakova T, Knoops L, Constantinescu S, Sigaux F, Meijerink JP,
Vandenberghe P, et al: PTPN2 negatively regulates oncogenic JAK1 in
T-cell acute lymphoblastic leukemia. Blood. 117:7090–7098. 2011.
View Article : Google Scholar : PubMed/NCBI
|
